Abstract 2926: The glycogen synthase kinase-3 inhibitor, 9-ING-41, synergizes with chemotherapy to inhibit pancreatic tumor growth in vivo
Li Ding(Sichuan University), Daniel D. Billadeau(Mayo Clinic), Vijay Sagar Madamsetty(Jacksonville College), Debabrata Mukhopadhyay(Jacksonville College), Daniel M. Schmitt(Fate Therapeutics (United States)), Jin‐San Zhang(Wenzhou Medical University), John R. Dube(Mayo Clinic in Arizona)
Cited by 0
Related Papers
SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells
|Oncogenesis|2013|336
Glycogen Synthase Kinase-3β Participates in Nuclear Factor κB–Mediated Gene Transcription and Cell Survival in Pancreatic Cancer Cells
|Cancer Research|2005|327
In vivo gene delivery mediated by non-viral vectors for cancer therapy
|Journal of Controlled Release|2020|240
Epigenetic Regulation of Autophagy by the Methyltransferase G9a
|Molecular and Cellular Biology|2013|217
Recent Trends of the Bio-Inspired Nanoparticles in Cancer Theranostics
|Frontiers in Pharmacology|2019|210